Aug 22, 2022 7:00am EDT Tonix Pharmaceuticals Initiates Enrollment in Phase 2 PREVAIL Study of TNX-102 SL for the Treatment of Long COVID
Aug 8, 2022 7:00am EDT Tonix Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Highlights
Aug 2, 2022 7:00am EDT Tonix Pharmaceuticals Receives Federal Grant from the National Institute on Drug Abuse (NIDA) to Advance Development of TNX-1300 as a Treatment for Cocaine Intoxication
Aug 1, 2022 7:00am EDT Tonix Pharmaceuticals Announces Issuance of U.S. Patent Covering Potentiated Intranasal Oxytocin (TNX-1900) for the Treatment of Pain
Jul 28, 2022 7:00am EDT Tonix Pharmaceuticals Announces Collaboration with Kenya Medical Research Institute to Develop TNX-801 in Kenya as a Vaccine for the Prevention of Monkeypox and Smallpox Infection
Jul 25, 2022 7:00am EDT Tonix Pharmaceuticals Announces Appointment of Sina Bavari, Ph.D. as Executive Vice President, Infectious Disease Research and Development
Jul 11, 2022 7:00am EDT Tonix Pharmaceuticals Announces Development of TNX-601 ER, a Potential Abuse Deterrent, Extended-Release Formulation of Tianeptine Oxalate for the Treatment of Major Depressive Disorder
Jul 6, 2022 7:00am EDT Tonix Pharmaceuticals Announces Presentation at the World Orphan Drug Congress USA
Jun 27, 2022 7:00am EDT Tonix Pharmaceuticals Announces Trial Design of New Phase 2 Clinical Study of TNX-1300 for Cocaine Intoxication
